Company Encyclopedia
View More
name
Rezolute
RZLT.US
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc.
1.946 T
RZLT.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Rezolute’s Promising Future: Buy Rating Backed by Strong Financials and Strategic Market Expansion

    Analyst Jason McCarthy from Maxim Group has reiterated a Buy rating on Rezolute, maintaining a price target of $20.00. This rating is supported by the company's strong financials, including $152.2 million in cash, and its promising Phase 3 study of ersodetug for congenital hyperinsulinism, expected to yield data by December. Rezolute's shares have risen over 100% this year, bolstered by interest in rare diseases and a recovering biotech market. Additionally, Wedbush also maintains a Buy rating with a $12.00 price target, highlighting the company's strategic market expansion plans.

    Tip Ranks·
    US
    RZLT
    +2.43%
    Tip Ranks·
    US
    RZLT
    +2.43%

    Rezolute Highlights Ersodetug Development at Investor Event

    Rezolute, Inc. held an investor event on November 10, 2025, to discuss the Ersodetug development program, highlighting unmet clinical needs in treating congenital and tumor hyperinsulinism. The company aims to improve patient outcomes and strengthen its position in the biopharmaceutical market. Analysts rate RZLT stock as a Buy with an $18.00 price target, though Spark's AI Analyst suggests a Neutral stance due to ongoing financial challenges. Rezolute focuses on therapies for metabolic and orphan diseases, with a current market cap of $923.1M.

    Tip Ranks·
    US
    RZLT
    +2.43%
    Tip Ranks·
    US
    RZLT
    +2.43%

    Rezolute (RZLT) Receives a Buy from Jefferies

    Jefferies analyst Maury Raycroft has maintained a Buy rating on Rezolute (RZLT) with a price target of $15.00. Raycroft, a 4-star analyst, has an average return of 11.0% and a 42.40% success rate. The consensus for Rezolute is a Strong Buy, with a price target consensus of $16.14.

    Tip Ranks·
    US
    RZLT
    +2.43%
    Tip Ranks·
    US
    RZLT
    +2.43%

    Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635 ( c ) ( 4 )

    REDWOOD CITY, Calif., Nov. 10, 2025 ( GLOBE NEWSWIRE ) -- Rezolute, Inc. ( NASDAQ: RZLT ) , ( "Rezolute" or the "Company" ) , a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced that it has granted as of October 31, 2025 equity inducement ...

    GlobeNewswire·
    US
    RZLT
    +2.43%
    GlobeNewswire·
    US
    RZLT
    +2.43%

    Rezolute (NASDAQ:RZLT) Sets New 12-Month High Following Better-Than-Expected Earnings

    Rezolute, Inc. (NASDAQ:RZLT) shares reached a new 52-week high of $10.94 after reporting better-than-expected quarterly earnings, with an EPS of ($0.18) surpassing estimates of ($0.27). Analysts have mixed ratings, with one Strong Buy, eight Buy, and one Sell. Institutional investors hold 82.97% of the stock, which has seen a 12.4% increase recently. The company focuses on therapies for metabolic diseases and is currently developing RZ358 for congenital hyperinsulinism.

    Market Beat·
    US
    RZLT
    +2.43%
    Market Beat·
    US
    RZLT
    +2.43%
    © 2025 Longbridge｜Disclaimer